CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), which utilize PD‐1/PD‐L1 or CTLA‐4 antibodies to block key checkpoint regulators, have been widely used in NSCLC patients in the clinic.6